Tesaro partners with Takeda in Asia, bagging a $340M deal for Zejula
Tesaro $TSRO has come through with a development and marketing partner for Japan.
Not surprisingly, Takeda stepped in to grab Japanese rights for niraparib (Zejula), its recently approved PARP inhibitor. Takeda gets rights on all indications in Japan and all indications except prostate cancer in South Korea, Taiwan, Russia and Australia.
In exchange, Tesaro – often named as a likely though pricey takeover target – gets $100 million upfront and another $240 million in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
